Saturday, 3 October 2026European Markets

Euro Surges 14% Against Dollar as Currency Rebalancing Reshapes European Monetary Landscape

The euro has gained 14% against the US dollar in 2025, while the pound has risen 7%, as the Dollar Index fell 10.8% in the first half of the period. Currency analysts are monitoring GBP/USD levels around $1.30 amid persistent dollar weakness and an upcoming Federal Reserve leadership transition as Jerome Powell prepares to step down.

LM Salvado
LM Salvado

March 21, 2026

Euro Surges 14% Against Dollar as Currency Rebalancing Reshapes European Monetary Landscape
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

The euro has surged 14% against the US dollar in 2025, marking one of the strongest currency rebalancing periods in recent years as the Dollar Index declined 10.8% in the first half of the period.1 The British pound gained 7% over the same timeframe, though recent pressure has pushed it to $1.3086, down 0.5% from earlier levels.2

Currency analysts are closely watching GBP/USD levels around the $1.30 threshold. Jordan Rochester at Mizuho Bank warns the pound could fall below $1.30, while Simon Phillips of No1 Currency notes ongoing pressure on sterling.2 The pound has also weakened to significant capitalagainst the euro, its lowest level since April 2023.2

The currency rebalancing coincides with a Federal Reserve leadership transition as Jerome Powell prepares to step down. Central banks are navigating this period carefully, with the Bank of Canada holding rates steady amid the shifting currency dynamics.1

European policymakers face a complex landscape as euro strength impacts export competitiveness and inflation dynamics.1

The dollar's weakness has persisted despite a modest recent recovery, with the Dollar Index still trading well below its earlier peaks. Market participants are assessing whether this represents a structural shift in global currency markets or a cyclical adjustment tied to Fed policy expectations.The yield movements reflect broader concerns about fiscal sustainability alongside the currency pressures.2 UK equity markets have shown resilience, with the FTSE 100 reaching a record high of 9,911 points.2

The euro's strength has also lifted other European currencies, with the Stoxx 600 index reaching a record 583.4 points.9% as investors adjusted to the new currency regime.2

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score4 source documents4 with a live linkVerifiability: Strong
  1. [1]News articleUk· November 12, 2025
    Pound hits two-year low against euro as Starmer under fire
  2. [2]News articleYahoo Finance· March 18, 2026
    Fed meeting live updates: Federal Reserve expected to hold rates steady, share outlook amid Iran oil shock
  3. [3]News articleYahoo Finance· December 31, 2025
    Stock market today: Dow, S&P 500, Nasdaq post double-digit gains in 2025 as AI trade powers market once again
  4. [4]News articleYahoo Finance· March 17, 2026
    Stock market today: Dow, S&P 500, Nasdaq rise for second day in a row with Fed decision on deck

In this story · Knowledge Files

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com